Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sunitinib malate (SUTENT) is an oral, multitargeted tyrosine kinase inhibitor, approved multinationally for the treatment of advanced RCC and of imatinib-resistant or - intolerant GIST. The purpose of this study was to explore potential biomarkers of sunitinib pharmacological activity via serial assessment of plasma levels of four soluble proteins from patients in a phase II study of advanced RCC: VEGF, soluble VEGFR-2 (sVEGFR-2), placenta growth factor (PlGF), and a novel soluble variant of VEGFR-3 (sVEGFR-3). METHODS: Sunitinib was administered at 50 mg/day on a 4/2 schedule (4 weeks on treatment, 2 weeks off treatment) to 63 patients with metastatic RCC after failure of first-line cytokine therapy. Predose plasma samples were collected on days 1 and 28 of each cycle and analyzed via ELISA. RESULTS: At the end of cycle 1, VEGF and PlGF levels increased >3-fold (relative to baseline) in 24/54 (44%) and 22/55 (40%) cases, respectively (P < 0.001). sVEGFR-2 levels decreased >or= 30% in 50/55 (91%) cases and >or= 20% in all cases (P < 0.001) during cycle 1, while sVEGFR-3 levels were decreased >or= 30% in 48 of 55 cases (87%), and >or= 20% in all but 2 cases. These levels tended to return to near-baseline after 2 weeks off treatment, indicating that these effects were dependent on drug exposure. Overall, significantly larger changes in VEGF, sVEGFR-2, and sVEGFR-3 levels were observed in patients exhibiting objective tumor response compared with those exhibiting stable disease or disease progression (P < 0.05 for each analyte; analysis not done for PlGF). CONCLUSION: Sunitinib treatment in advanced RCC patients leads to modulation of plasma levels of circulating proteins involved in VEGF signaling, including soluble forms of two VEGF receptors. This panel of proteins may be of value as biomarkers of the pharmacological and clinical activity of sunitinib in RCC, and of angiogenic processes in cancer and other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Budagian, V., Bulanova, E., Orinska, Z., Duitman, E. H., Brandt, K., Ludwig, A., Hartmann, D., Lemke, G., Säftig, P., & Bulfone‐Paus, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9324-9339.2005 · Cited by 84
RetractedThe biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 2,157
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Self-citationThe role of pericytes in blood-vessel formation and maintenance
Bergers, G., & Song, S. (2005) · Neuro-Oncology · doi:10.1215/s1152851705000232 · Cited by 1,584
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
Self-citationFaivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Self-citationSignal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson-Welsh, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,062
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N., & Cherrington, J. M. (2003) · PubMed · Cited by 685
DeSilva, B., Smith, W., Weiner, R., Kelley, M., Smolec, J., Lee, B., Khan, M., Tacey, R., Hill, H., & Celniker, A. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000003390.51761.3d · Cited by 623
Sun, L., Liang, C., Shirazian, S., Zhou, Y., Miller, T., Cui, J., Fukuda, J. Y., Chu, J.-Y., Nematalla, A., Wang, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204183 · Cited by 521
Fiedler, W., Serve, H., Döhner, H., Schwittay, M., Ottmann, O. G., O'Farrell, A.-M., Bello, C. L., Allred, R., Manning, W. C., Cherrington, J. M., et al. (2005) · Blood · doi:10.1182/blood-2004-05-1846 · Cited by 490
Self-citationPDGF receptors as cancer drug targets
Pietras, K., Sjöblom, T., Rubin, K., Heldin, C.-H., & Östman, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00089-8 · Cited by 465
He, Y., Rajantie, I., Pajusola, K., Jeltsch, M., Holopainen, T., Yla-Herttuala, S., Harding, T., Jooss, K., Takahashi, T., & Alitalo, K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4576 · Cited by 410
Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
Kwiatkowski, D. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.446 · Cited by 387
RENAL CELL CARCINOMA 2005: NEW FRONTIERS IN STAGING, PROGNOSTICATION AND TARGETED MOLECULAR THERAPY
LAM, J. S., SHVARTS, O., LEPPERT, J. T., FIGLIN, R. A., & BELLDEGRUN, A. S. (2005) · Journal of Urology · doi:10.1097/01.ju.0000165693.68449.c3 · Cited by 372
Levi, E., Fridman, R., Miao, H. Q., Ma, Y. S., Yayon, A., & Vlodavsky, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.7069 · Cited by 351
Sather, S., Kenyon, K. D., Lefkowitz, J. B., Liang, X., Varnum, B. C., Henson, P. M., & Graham, D. K. (2007) · Blood · doi:10.1182/blood-2006-05-021634 · Cited by 332
Murray, L. J., Abrams, T. J., Long, K. R., Ngai, T. J., Olson, L. M., Hong, W., Keast, P. K., Brassard, J. A., O'Farrell, A. M., Cherrington, J. M., et al. (2003) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000006873.65590.68 · Cited by 305
Abrams, T. J., Murray, L. J., Pesenti, E. A., Holway, V. W., Colombo, T., Lee, L. B., Cherrington, J. M., & Pryer, N. (2003) · PubMed · Cited by 282
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours
Terris, Scoazec, Rubbia, Bregeaud, Pepper, Ruszniewski, Belghiti, FLÉjou, & Degott (1998) · Histopathology · doi:10.1046/j.1365-2559.1998.00321.x · Cited by 279
Berlin, L. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.170.2.9456928 · Cited by 272
Schueneman, A. J., Himmelfarb, E. A., Geng, L., Tan, J., Donnelly, E. F., Mendel, D. B., McMahon, G., & Hallahan, D. E. (2003) · PubMed · Cited by 259
Price, D. J., Miralem, T., Jiang, S., Steinberg, R., & Avraham, H. K. (2001) · PubMed · Cited by 243
Mendel, D. B., Schreck, R., West, D. C., Li, G., Strawn, L. M., Tanciongco, S. S., Vasile, S., Shawver, L. K., & Cherrington, J. M. (2000) · PubMed · Cited by 214
Ebos, J. M. L., Bocci, G., Man, S., Thorpe, P. E., Hicklin, D. J., Zhou, D., Jia, X., & Kerbel, R. S. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.315.2.6 · Cited by 211
Christofori, G. (1995) · Molecular Endocrinology · doi:10.1210/me.9.12.1760 · Cited by 198
Targeting lymphangiogenesis to prevent tumour metastasis
Achen, M. G., Mann, G. B., & Stacker, S. A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603120 · Cited by 166
Bocci, G., Man, S., Green, S. K., Francia, G., Ebos, J. M. L., du Manoir, J. M., Weinerman, A., Emmenegger, U., Ma, L., Thorpe, P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0401 · Cited by 162
VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis
Tjwa, M., Luttun, A., Autiero, M., & Carmeliet, P. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0776-3 · Cited by 158
Esteva, F. J., Cheli, C. D., Fritsche, H. A., Fornier, M. N., Slamon, D. J., Thiel, R. P., Lüftner, D., & Ghani, F. (2005) · Breast Cancer Research · doi:10.1186/bcr1020 · Cited by 154
Reusch, P., Barleon, B., Weindel, K., Martiny‐Baron, G., Gödde, A., Siemeister, G., & Marmé, D. (2001) · Angiogenesis · doi:10.1023/a:1012226627813 · Cited by 136
Bello, C. L., Sherman, L. J., Zhou, J., Verkh, L., Smeraglia, J., Mount, J., & Klamerus, K. J. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200603000-00015 · Cited by 136
Self-citationDrevs, J., Zirrgiebel, U., Schmidt-Gersbach, C., Mross, K. B., Medinger, M., Lee, L., Pinheiro, J. C., Wood, J. M., Thomas, A., Unger, C., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi118 · Cited by 121
Nath, D., Williamson, N. J., Jarvis, R., & Murphy, G. (2014) · Journal of Cell Science · doi:10.1242/jcs.152595 · Cited by 111
Nath, D., Williamson, N. J., Jarvis, R., & Murphy, G. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.6.1213 · Cited by 105
Baron, A. T., Cora, E. M., Lafky, J. M., Boardman, C. H., Buenafe, M. C., RADEMAKER, A. W., Liu, D., Fishman, D. A., Podratz, K. C., & Maihle, N. J. (2003) · PubMed · Cited by 97
c-Met Ectodomain Shedding Rate Correlates with Malignant Potential
Athauda, G., Giubellino, A., Coleman, J., Horak, C. E., Steeg, P. S., Lee, M.-J., Trepel, J. B., Wimberly, J., Sun, J., Coxon, A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0250 · Cited by 89
Soluble kit receptor in human serum
Wypych, J., Bennett, L., Schwartz, M., Clogston, C. L., Lu, H., Broudy, V., Bartley, T. D., Parker, V., & Langley, K. E. (1995) · Blood · doi:10.1182/blood.v85.1.66.bloodjournal85166 · Cited by 70
Lee, L., Sharma, S., Morgan, B., ALLEGRINI, P. R., Schnell, C., Brueggen, J., Cozens, R. M., Horsfield, M. A., Guenther, C., Steward, W. P., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0120-6 · Cited by 63
Bono, P., Krause, A., von Mehren, M., Heinrich, M. C., Blanke, C. D., Dimitrijević, S., Demetri, G. D., & Joensuu, H. (2004) · Blood · doi:10.1182/blood-2003-10-3443 · Cited by 62
Fox, S. B., Turley, H., Cheale, M., Blázquez, C., Roberts, H., James, N. H., Cook, N., Harris, A. L., & Gatter, K. C. (2004) · The Journal of Pathology · doi:10.1002/path.1520 · Cited by 55
Giles, F. J., Bellamy, W. T., Estrov, Z. E., O'Brien, S. M., Verstovšek, S., Ravandi, F., Beran, M., Bycott, P. W., Pithavala, Y. K., Steinfeldt, H. M., et al. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.10.024 · Cited by 52
Cited by
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Llovet, J. M., Peña, C. E. A., Lathia, C. D., Shan, M., Meinhardt, G., & Bruix, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2175 · Cited by 559
Burstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., Lehman, M., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489
Self-citationPredictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Hegde, P. S., Wallin, J. J., & Mancao, C. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.002 · Cited by 453
Metadata
- Authors
- DePrimo, S. E., Bello, C. L., Smeraglia, J., Baum, C. M., Spinella, D., Rini, B. I., Michaelson, M. D., & Motzer, R. J.
- Venue
- Journal of Translational Medicine
- Published
- 2007-07-02
- Volume
- 5
- Issue
- 1
- Pages
- 32-32
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2150452646
- Cited by
- 318
- References
- 47
- FWCI
- 23.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.